Announcement on Convening Performance Briefing for 2025 and Q1 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening Performance Briefing for 2025 and Q1 2026
Filed with SSE · · 3 pages · Chinese
Release
Chongqing Genrix Biopharmaceutical Co., Ltd. on 6ix
Earlier from Chongqing Genrix Biopharmaceutical
- Announcement on Renewing Engagement of Audit Institution for 2026
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Publicity Explanation and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on List of Initially Granted Incentive Objects in the 2026 Restricted Stock Incentive Plan
- Notice on Convening the 2nd Extraordinary General Meeting in 2026
- Announcement on Opening of a New Special Account for Raised Funds and Signing of a Tripartite Supervision Agreement on Special Account Deposit of Raised Funds
Later from Chongqing Genrix Biopharmaceutical
- Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of GR1803 Injection (Subcutaneous Injection)
- Announcement on License Agreement for the GR1803 Project
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
- Announcement on Voluntary Disclosure of the Approval for Market Launch of Siromivimab Injection for Passive Immunization Indication in Adults Exposed to Rabies Virus
Follow Chongqing Genrix Biopharmaceutical into a list and get an email when it puts out news.
Follow Chongqing Genrix Biopharmaceutical